| Literature DB >> 34395318 |
Awal Prasetyo1,2, Jethro Budiman3, Udadi Sadhana1,2.
Abstract
INTRODUCTION: Nasopharyngeal carcinoma (NPC) is a rare and aggressive head and neck squamous cell carcinoma worldwide. Tumor-infiltrating lymphocytes (TILs) have been studied and reported to be effective targets of drugs on cancer and were related to the prognostic value. The aim of the study was to look systematically into the current literature and carefully analyze the results to explore the relationship of TILs and NPC.Entities:
Keywords: Immunology; Nasopharyngeal Carcinoma; Tumor-Infiltrating Lymphocytes
Year: 2021 PMID: 34395318 PMCID: PMC8339891 DOI: 10.22038/ijorl.2021.51405.2733
Source DB: PubMed Journal: Iran J Otorhinolaryngol ISSN: 2251-7251
Study characteristic
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1. | Almangush A, Finland, 2018[ | Cohort | 115 | The prognostic significance of TILs in NPC |
NPC with low intra-tumoral TILs had poor OS (HR: 2.55, 95%CI: 1.60-4.50, P<0.001) and poor DSS (HR: 2.02, 95%CI: 1.16-3.52, p: 0.015). Keratinized tumors with low intra-tumoral TILs were associated with a poor OS (HR: 3.94, 95%CI: 2.17-7.15, P< 0.001) and a poor DSS (HR:2.97, 95%CI: 1.46-6.05, p: 0.009). |
| 2. | Chan OSH, Hongkong, 2017[ | Cohort | 161 | Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer (the prognostic significance of TILS in NPC) |
75% of tumors expressed PD-L1 on TILs and 24% on TC. High CD8+ TILs were associated with better OS (HR: 0.53, 95%CI: 0.34-0.84, P: 0.0059). and PFS (HR: 0.57, 95%CI: 0.38-0.85, p: 0.006). |
| 3. | He J, China, 2012[ | Experimental | 15 | Ex vivo expansion of TILs from NPC for adoptive immunotherapy |
Young TIL cultures comprised of more than 90% of CD3+ T cells, a variable percentage of CD3+CD8+ and CD3+ CD4+ T cells, and less than 10% of CD3-CD16+ NK cells, a similar phenotype of EBV-CTL cultures from PBMCs. TIL cultures secreted high levels of the Th1 cytokines, IFNγ and TNF-α, and low levels of the Th2 cytokines, IL-4 and IL-10. Young TILs could recognize autologous EBV-transformed B lymphoblast cell lines, but not autologous EBV-negative blast cells or allogeneic EBV-negative tumor cells. |
| 4. | Larbcharoensub N, Thailand, 2018[ | Cohort | 114 | Characterization of PD-L1 and PD-1 expression and CD8+ TILs in Epstein-Barr Virus-associated NPC (the prognostic significance of TILS in NPC) |
PD-L1 was expressed in ≥ 1% of TCs in 69% of patients, in ≥ 50% of TCs in 12% of patients, and ≥ 5% of either TCs or infiltrating immune cells in 71% of patients. CD8+ TILs were present in tumors from all patients. High CD8+ TILs levels in NPC were associated with a longer OS. |
| 5. | Li J, China, 2015[ | Experimental | 23 | The safety and antitumor activity of ACT using expanded TILs following CCRT in patients with locoregionally advanced NPC |
Three patients failed to produce sufficient TILs (drop out). Only mild AEs including grade 3 neutropenia (1/23, 5%) consistent with immune-related causes, were observed. 19 of 20 patients exhibited an objective antitumor response, and 18 patients displayed DFS longer than 12 mo after ACT. |
| 6. | Lu J, China, 2018[ | Cohort | 197 | Analysis of inflammatory cell infiltration and the prognostic |
The patients with NPC with a low density of FOXP3+, CD8+ TILs, neutrophils, and mast cells showed a significantly longer OS and PFS (p: 0.006, p: 0.018, p: 0.002). The prognostic impacts of CD8+ TILs (HR: 1.700, p: 0.036) and FOXP3+ (HR:1.714, p: 0.034) on OS were not proved. |
| 7. | Luo M, China, 2019[ | Cross sectional | NPC: 12 | TILs in NPC based on gene expression |
NPC samples contained a higher proportion for M1 macrophages, whereas memory B cells and CD4 memory resting T cells were relatively lower. High M1 macrophages, memory B cells, and CD4 memory resting T cells were associated with a better survival rate (p: 0.286, p: 0.509, p: 0.048). |
| 8. | Oudejans J J, Indonesia, 2002[ | Cohort | 43 | The prognostic significance of GrB/ CD8+ TILs in NPC |
The presence of a high percentage (>25%) of GrB + TILs appeared to be a very strong predictor of a rapid fatal clinical outcome, independent of stage. |
| 9. | Ono T, Japan, 2018[ | Cohort | 66 | The prognostic significance of TILs in NPC |
CD8+ TILs were significant predictive factor for PFS (HR: 0.36, 95%CI: 0.15-0.88, p: 0.025) and OS (HR: 0.30, 95%CI: 0.12-0.73, p: 0.008). |
| 10. | Ooft ML, Netherland, 2017[ | Cohort | 92 | The prognostic significance of TILs in NPC |
EBV positive NPC contains significantly more CD3+, CD4+, and CD8+ TILs than EBV negative NPC. In the whole NPC group, increased CD8+ count is associated with better OS (HR: 0.219. 95%CI: 0.075-0.640), but also in cases with PDL1 co-expression (HR: 0.073, 95%CI: 0.010-0.556). In EBV positive NPC co-expression of CD8+ and PDL-1 showed better DFS (HR:0.407, 95%CI: 0.195-0.850) and OS (HR 0.170, 95%CI: 0.037–0.787). |
| 11. | Wang Y, China, 2018[ | Cohort | Training set: 591 | The prognostic significance of TILs in NPC |
High TILs in the training set were significantly associated with favorable DFS (HR: 0.41, 95%CI: 0.28-0.58, p< 0.001), OS (HR 0.42, 95%CI: 0.27-0.64, p < 0.001), DMFS, (HR: 0.37, 95%CI: 0.23-0.58, p< 0.001 and LRRFS (HR: 0.43, 95%CI :0.25-0.73, p: 0.002). |
| 12. | Zhang Y, China, 2010[ | Cohort | 106 | The prognostic significance of TILs in NPC |
The density of FOXP3+ TILs or Foxp3+ TILs combined with GrB+ TILs together were associated with better OS and PFS (p< 0.01). Low density of CD8+TILs or high ratio of FOXP3+TILs to CD8+TILs was correlated with better PFS in early-stage patients (Stages I and II, p< 0.05). |
Abbreviation: ACT: adoptive cell therapy AEs: adverse events CCRT: concurrent chemoradiotherapy CD: cluster of differentiation CI: confidence interval DFS: disease-free survival DMFS: distant metastasis-free survival DSS: disease specific survival EBV: epstein-barr virus FOXP3: forkhead box p3 GrB: Granzyme B HR: hazard ratio IFN-γ: interferon-gamma IL: interleukin LRRFS: local-regional recurrent free survival
mo: month NK: natural killer NP: non-malignant nasopharyngeal OS: overall survival p: probability PBMC: peripheral blood mononuclear cells PFS: progression-free survival Treg: regulatory T cells TCs: tumor cells
Fig 1Preferred reporting items for systematic reviews and meta-analysis (PRISMA)
Newcastle-Ottawa scale adapted for cross-sectional study
| No. | First author, year | Selection | Comparability | Outcome | Total | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 1 | 2 | ||||
| 1. | Luo M, 2019 ( | ** | ** | * | 5 | ||||
Newcastle-Ottawa scale (cohort study)
| No. | First author, year | Selection | Comparability | Outcome | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 1 | 2 | 3 | ||||
| 1. | Almangush A, 2018[ | * | * | * | * | * | 5 | |||
| 2. | Larbcharoensub N, 2018[ | * | * | * | * | * | 5 | |||
| 3. | Lu J, 2018[ | * | * | * | * | * | 5 | |||
| 4. | Ono T, 2018[ | * | * | * | * | * | 5 | |||
| 5. | Wang Y, 2018[ | * | * | * | * | * | * | * | 7 | |
| 6. | Chan OSH, 2017[ | * | * | * | * | * | 5 | |||
| 7. | Ooft ML, 2017[ | * | * | * | * | * | 5 | |||
| 8. | Zhang Y, 2010[ | * | * | * | * | * | 5 | |||
| 9. | Oudejans J J, 2002[ | * | * | * | * | * | 5 | |||
*Maximum point for comparability were 2
Cochrane risk of bias 1: Li J, 2015[26]
|
|
|
|
|
|---|---|---|---|
| 1. |
|
|
|
| 2. | Domain 2 | risk of bias due to deviations from the intended interventions (effect of adhering to intervention) | low risk |
| 3. | Domain 3 | missing outcome data | low risk |
| 4. | Domain 4 | risk of bias in measurement of the outcome | low risk |
| 5. | Domain 5 | risk of bias in selection of the reported result | low risk |
Cochrane risk of bias 2: He J, 201227
|
|
|
|
|
|---|---|---|---|
| 1. | Domain 1 |
|
|
| 2. | Domain 2 | risk of bias due to deviations from the intended interventions (effect of adhering to intervention) | low risk |
| 3. | Domain 3 | missing outcome data | low risk |
| 4. | Domain 4 | risk of bias in measurement of the outcome | low risk |
| 5. | Domain 5 | risk of bias in selection of the reported result | low risk |